Skip to content
CIVIC HERALD
HR 9699 · 119th Congress · HouseIn committee

Drug Deal Disclosure Act

In plain language: This bill requires the federal government to create a public, searchable online database of all contracts, communications, and meeting records from recent pricing deals negotiated between federal agencies and major drug companies. These agreements include commitments on drug discounts, direct-to-consumer sales platforms, tariff exemptions, and special regulatory treatment for pharmaceutical manufacturers. Additionally, federal budget and accountability offices must publish an independent economic analysis evaluating how these deals affect out-of-pocket prescription costs for insured and uninsured Americans, generic drug competition, and government healthcare spending.

Provisional: our plain-language summary, pending review.

Provisionalunreviewed: impact, issue tags, provisions, stakeholders, summary
People affected—not determinable from the text provided
Fiscal magnitude—no CBO estimate published
Reach26provisional · pending reviewrigor: heuristic llm
Your matchSign in →See how this matches your values.

Issues

What this bill touches.

Ethics & oversight+50

The sign shows the bill's direction on each issue (+ toward, − away); the number is its magnitude. Color never encodes good or bad, and never party.

Who it affects

Who it helps · who it burdens.

Who it helps

  • Public, healthcare consumers, and researchersGain centralized, searchable, and downloadable public access to federal drug agreements, executive communications, meeting records, and detailed economic impact analyses.provisional

Who it burdens

  • Department of Health and Human ServicesMust compile, publish, and maintain an online, searchable database of all records, communications, and contracts related to federal drug manufacturer agreements, and submit reports to Congress detailing any withheld or redacted records.provisional
  • Pharmaceutical manufacturers with federal agreementsFace public disclosure of their federal agreements, communications, meeting notes, directives, and contract terms concerning drug pricing, direct-to-consumer sales, tariff exemptions, and regulatory concessions.provisional
  • Congressional Budget Office and Government Accountability OfficeMust jointly research, prepare, and publish a comprehensive report analyzing the economic, budgetary, healthcare program, and market competition impacts of disclosed drug manufacturer agreements within 90 days of document release.provisional

Dollar-level funding (FEC sector totals) is coming in a later phase.

What it does

The provisions, in plain language.

  1. Directs the Department of Health and Human Services to publish an online, searchable database of all records, contracts, and communications concerning federal agreements made with drug manufacturers on or after January 20, 2025, regarding drug pricing, direct-to-consumer sales platforms, tariff exemptions, or regulatory concessions.

    Sec. 2(a)(1)-(2)provisional

  2. Requires the Department of Health and Human Services to publicly disclose any new or modified federal agreements with drug manufacturers within 30 days of ratification.

    Sec. 2(a)(3)provisional

  3. Prohibits federal agencies from redacting, delaying, or withholding any drug agreement records on the grounds of political sensitivity or reputational harm.

    Sec. 2(b)provisional

  4. Allows the Department of Health and Human Services to redact proprietary or legally protected pricing data from published agreements only if it discloses whether it received confidential pricing data and publishes a written justification in the Federal Register and to Congress.

    Sec. 2(c)provisional

  5. Directs the Congressional Budget Office and the Government Accountability Office to jointly publish a report analyzing the economic and budget effects of the disclosed agreements, including consumer out-of-pocket savings and impacts on Medicare, Medicaid, and drug price competition.

    Sec. 4provisional

How your members of Congress line up

Loading your members of Congress…

Timeline

How it moved.

  1. Jul 15, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Jul 15, 2026Introduced in House
  3. Jul 15, 2026Introduced in House

The original text

Read it for yourself.

Read the original text →

Sources & provenance

Congress.govrefreshed 17 days ago

Checking your session…